Eli Lilly to close Terre Haute animal enzyme plant
The plant closure will affect 23 plant employees, all of whom will be offered comparable positions at a Lilly plant near Clinton that employs about 500 workers.
Eli Lilly and Co.
Articles
More patients help drug firms pass ‘valley of death’
In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.
FDA approves Lilly, Boehringer diabetes drug
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.
Most drug money in Indiana funds research. Is that good?
With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That’s not the same thing as paying to market drugs, but it’s hardly without controversy.
Roche drug trial backs Lilly on Alzheimer’s findings
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
Indy patients love their doctors
Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Doctors’ drug money
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
Report: Indiana boasts four nation-leading life sciences clusters
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
Lilly wins EU backing for version of insulin drug
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
Lilly, IU expect $25M plan to create new model for drug R&D
A new research consortium spearheaded by the Indiana University School of Medicine and Eli Lilly and Co. could bring in $25 million to $50 million over five years to create a new approach for developing drugs that provide more precise treatment for small groups of patients.
Former Riley Hospital CEO Pescovitz to join Eli Lilly
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
Lilly consolidated into testosterone drug lawsuit
The decision to collect cases before one court comes after the U.S. Food and Drug Administration said it will re-examine the safety of testosterone-replacement drugs after studies showed the medicine posed an increased risk of heart attack and stroke.
Costly drugs force cancer docs to weigh price with therapy
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
Lilly, Sanofi seek to sell erection drug Cialis without prescription
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
Ex-Lilly partner wins latest suit over Actos’ cancer risk
Takeda Pharmaceutical was found not liable for the bladder cancer of two women who used its Actos diabetes medication in the company’s latest trial over the drug. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Takeda denies hiding Actos cancer risks in Nevada trial
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
Drugmaker hid diabetes drug’s cancer risks, lawyer says
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
UPDATE: AstraZeneca board rejects new offer from Pfizer
Pfizer’s proposed deal would have been the richest acquisition ever among drugmakers and the third-biggest deal in any industry, according to figures from research firm Dealogic.
Lilly’s latest sales strategy: the soft sell
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
Lilly CEO elected chairman of United Way Worldwide board
United Way Worldwide President and CEO Brian Gallagher said John Lechleiter will help strengthen the not-for-profit network's capacity to meet growing human needs around the world.